A drug combination approved last year by the U.S. Food and Drug Administration may have a greater effect for men with melanoma than previously reported, according to a new analysis of clinical trial data.
Publications
IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
Prima BioMed Ltd (ASX: PRR) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal.
Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma
Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) may underestimate the treatment response in patients with advanced melanoma treated with pembrolizumab , a study published in the Journal of Clinical Oncology has shown.1
Study Links Increased Risk of Melanoma to Use of Sildenafil
Researchers have found that sildenafil — a drug used to treat erectile dysfunction and pulmonary hypertension — is linked to an increased risk of melanoma by promoting cGMP-cGKI signaling cascade. The results, “Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth,” were published in the journal Cell Reports.